Dr. Davies is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd, Unit 0904
Houston, TX 77030Phone+1 713-792-7090Fax+1 713-563-3424- Is this information wrong?
Education & Training
- University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 2004 - 2007
- Massachusetts General HospitalResidency, Internal Medicine, 2001 - 2004
- McGovern Medical School at UTHealthClass of 2001
Certifications & Licensure
- FL State Medical License 2021 - Present
- WA State Medical License 2023 - 2026
- GA State Medical License 2023 - 2025
- OK State Medical License 2020 - 2025
- AZ State Medical License 2023 - 2025
- TX State Medical License 2004 - 2025
- TN State Medical License 2023 - 2025
- Join now to see all
Clinical Trials
- An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor Start of enrollment: 2012 Sep 01
- Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma Start of enrollment: 2014 Mar 24
- CNS and Extracranial Tumor Tissues, CSF, and Blood From Patients With Melanoma Brain Metastases Start of enrollment: 2014 Aug 12
Publications & Presentations
PubMed
- Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations.Funda Meric-Bernstam, Michael W Lloyd, Soner Koc, Yvonne A Evrard, Lisa Meier McShane, Michael T Lewis, Kurt W Evans, Dali Li, Lawrence V Rubinstein, Alana L Welm, Den...> ;Molecular Cancer Therapeutics. 2024 Apr 20
- Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma.Usman Baqai, Alison M Kurimchak, Isabella V Trachtenberg, Timothy J Purwin, Jelan I Haj, Anna Han, Kristine Luo, Nikole Fandino Pachon, Angela Jeon, Vivian Chua, Micha...> ;The Journal of Biological Chemistry. 2023 Dec 1
- ARF6-dependent endocytic trafficking of the Interferon-γ receptor drives adaptive immune resistance in cancer.Yinshen Wee, Junhua Wang, Emily C Wilson, Coulson P Rich, Aaron Rogers, Zongzhong Tong, Evelyn DeGroot, Y N Vashisht Gopal, Michael A Davies, H Atakan Ekiz, Joshua K H...> ;Biorxiv. 2023 Oct 2
- Join now to see all
Journal Articles
- Publisher Correction: Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable MelanomaScott Woodman, Alexander J Lazar, Michael A Davies, Neil Gross, Sapna P Patel, Isabella C Glitza, Ehab Hanna, Stephen Y Lai, Richard Ehlers, Amy Hessel, Padmanee Sharm..., Nature
- Author Correction: Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable MelanomaJanice N Cormier, Ehab Hanna, Padmanee Sharma, Jennifer A Wargo, Isabella C Glitza, Sapna P Patel, Adi Diab, Jeffrey E Lee, Richard Royal, Randal Weber, Patrick Hwu, J..., Nature
- Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable MelanomaRichard Royal, Alexander J Lazar, Adi Diab, Sapna P Patel, Jeffrey E Lee, Padmanee Sharma, Patrick Hwu, Randal Weber, Jeffrey Gershenwald, Carol Lewis, Richard Ehlers,..., Nature
- Join now to see all
Press Mentions
- Physician-Scientist Focused on Improving Brain Metastases TreatmentFebruary 17th, 2023
- New Cell-Based Therapy for Melanoma More Effective Than Existing Treatment, Trial FindsSeptember 10th, 2022
- New Cell-Based Therapy for Melanoma Is More Effective Than Existing Treatment, Trial SaysSeptember 10th, 2022
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
- University of Texas M.D. Anderson Cancer CenterHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: